Reblozyl Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Luspatercept

Indications/Uses

Adults w/ transfusion-dependent anaemia due to very low, low & intermediate-risk myelodysplastic syndromes (MDS) w/ ring sideroblasts, who had unsatisfactory response to or are ineligible for erythropoietin-based therapy. Adults w/ anaemia associated w/ transfusion- & non-transfusion-dependent β-thalassaemia.

Dosage/Direction for Use

SC MDS Initially 1 mg/kg once every 3 wk. Patient who are not RBC transfusion-free after at least 2 consecutive doses at initial dose Increase dose to 1.33 mg/kg, then may further increase to 1.75 mg/kg if patient is not RBC transfusion-free after at least 2 consecutive 1.33 mg/kg doses. Max: 1.75 mg/kg every 3 wk. Transfusion-dependent β-thalassaemia Initially 1 mg/kg. Patient who do not achieve after ≥2 consecutive doses (6 wk) Increase dose to 1.25 mg/kg. Max: 1.25 mg/kg every 3 wk. Non-transfusion-dependent β-thalassaemia Patient who do not achieve or maintain a response after ≥2 consecutive doses (6 wk) Increase dose by one dose level. Max: 1.25 mg/kg every 3 wk.

Contraindications

Hypersensitivity. Pregnancy.

MIMS Class

Haematopoietic Agents

ATC Classification

B03XA06 - luspatercept ; Belongs to the class of other antianemic preparations. Used in the treatment of anemia.

Regulatory Classification

POM

Presentation/Packing

Form

Reblozyl powd for soln for inj 25 mg

Packing/Price

1's

Form

Reblozyl powd for soln for inj 75 mg

Packing/Price

1's

Reblozyl

luspatercept

Manufacturer:

Patheon Italia